Boehringer In­gel­heim flies the white flag as last hold­out sur­ren­ders in war over a $20B Ab­b­Vie gold mine

Af­ter bat­tling it out in the courts as the last big hold­out in the fight over Ab­b­Vie’s Hu­mi­ra patents, Boehringer In­gel­heim has dropped neat­ly in­to the line­up for a 2023 biosim­i­lar roll­out.

The Ger­man out­fit will now in­tro­duce its biosim­i­lar on Ju­ly 1, 2023, giv­ing Ab­b­Vie a com­plete vic­to­ry in its quest to main­tain com­plete con­trol of the world’s biggest drug fran­chise for more than 4 years. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA